Eli Lilly and Company (NYSE: LLY) announced the completion of its acquisition of Versanis Bio.
Versanis Bio is a Boston, MA-based company leveraging activin biology to develop therapeutics for obesity and cardiometabolic disease.
The acquisition expands Lilly’s portfolio to include Versanis’ lead asset, bimagrumab, which is currently being assessed in a Phase 2b study alone and in combination with semaglutide in adults living with overweight or obesity.
Under the terms of the agreement, Versanis shareholders could receive up to $1.925 billion in cash, inclusive of the upfront payment and subsequent payments upon achievement of certain development and sales milestones.
FinSMEs
15/08/2023